On the public citation graph

The NIMH-MATRICS Consensus Statement on Negative Symptoms

https://doi.org/10.1093/schbul/sbj053
0 signed · 1298 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/archpsyc.1982.04290070020005openalex-snapshot
Negative Symptoms in Schizophrenia
inferredcites →https://doi.org/10.1001/archpsyc.1985.01790240097011openalex-snapshot
Positive and Negative Symptoms and Jackson
inferredcites →https://doi.org/10.1001/archpsyc.58.2.165openalex-snapshot
A Separate Disease Within the Syndrome of Schizophrenia
inferredcites →https://doi.org/10.1016/0165-1781(89)90153-4openalex-snapshot
The schedule for the deficit syndrome: An instrument for research in schizophrenia
inferredcites →https://doi.org/10.1016/j.comppsych.2003.09.006openalex-snapshot
The sensitivity of quality-of-life scale WHOQOL-100 to psychopathological measures in schizophrenia
inferredcites →https://doi.org/10.1016/s0893-133x(99)00122-0openalex-snapshot
Assessing the Efficacy of Treatments for the Deficit Syndrome of Schizophrenia
inferredcites →https://doi.org/10.1016/s0920-9964(98)00105-4openalex-snapshot
Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials
inferredcites →https://doi.org/10.1034/j.1600-0447.2000.00006.xopenalex-snapshot
Schizophrenia and quality of life
inferredcites →https://doi.org/10.1034/j.1600-0447.2000.102004303.xopenalex-snapshot
The relationship of symptoms and level of functioning in schizophrenia to general wellbeing and the Quality of Life Scale
inferredcites →https://doi.org/10.1080/j.1440-1614.2005.01608.xopenalex-snapshot
Relative Contributions of Psychiatric Symptoms and Neuropsychological Functioning to Quality of Life in First-Episode Psychosis
inferredcites →https://doi.org/10.1093/schbul/1.11.61openalex-snapshot
Part III. Speculations on the Processes That Underlie Schizophrenic Symptoms and Signs
inferredcites →https://doi.org/10.1093/schbul/11.1.61openalex-snapshot
Social Adjustment and Cognitive Performance of High-Risk Children
inferredcites →https://doi.org/10.1093/schbul/13.2.261openalex-snapshot
The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia
inferredcites →https://doi.org/10.1093/schbul/sbi039openalex-snapshot
Food and Drug Administration Perspective on Negative Symptoms in Schizophrenia as a Target for a Drug Treatment Claim
inferredcites →https://doi.org/10.1093/schbul/sbi049openalex-snapshot
Social Cognition in Schizophrenia: Recommendations from the Measurement and Treatment Research to Improve Cognition in Schizophrenia New Approaches Conference
inferredcites →https://doi.org/10.1093/schbul/sbi064openalex-snapshot
The Factorial Structure of the Schedule for the Deficit Syndrome in Schizophrenia
inferredcites →https://doi.org/10.1093/schbul/sbj009openalex-snapshot
Anhedonia in Schizophrenia: A Review of Assessment Strategies
inferredcites →https://doi.org/10.1093/schbul/sbj011openalex-snapshot
Negative Symptoms and Cognitive Deficits: What Is the Nature of Their Relationship?
inferredcites →https://doi.org/10.1093/schbul/sbj013openalex-snapshot
The Structure of Negative Symptoms Within Schizophrenia: Implications for Assessment
inferredcites →https://doi.org/10.1093/schbul/sbj054openalex-snapshot
Subdomains Within the Negative Symptoms of Schizophrenia: Commentary
inferredcites →https://doi.org/10.1093/schbul/sbj055openalex-snapshot
Treatment of Schizophrenia Negative Symptoms: Future Prospects
inferredcites →https://doi.org/10.1097/00005053-199404000-00001openalex-snapshot
Domains of Psychopathology
inferredcites →https://doi.org/10.1176/ajp.145.5.578openalex-snapshot
Deficit and nondeficit forms of schizophrenia: the concept
inferredcites →https://doi.org/10.1176/ajp.153.3.321openalex-snapshot
What are the functional consequences of neurocognitive deficits in schizophrenia?
inferredcites →https://doi.org/10.1186/1477-7525-2-15openalex-snapshot
Social function in schizophrenia and schizoaffective disorder: associations with personality, symptoms and neurocognition.
inferredcites →https://doi.org/10.1682/jrrd.2004.02.0225openalex-snapshot
Attributional style and symptoms as predictors of social function in schizophrenia

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4103311openalex-extracted
Smartphone-Based Mobility Metrics Capture Daily Social Motivation and Behavior in Schizophrenia
inferred← citeshttps://doi.org/10.1001/archgenpsychiatry.2011.129openalex-snapshot
Randomized Trial to Evaluate the Efficacy of Cognitive Therapy for Low-Functioning Patients With Schizophrenia
inferred← citeshttps://doi.org/10.1001/archgenpsychiatry.2011.141openalex-snapshot
Cognitive Therapy for Negative Symptoms of Schizophrenia
inferred← citeshttps://doi.org/10.1001/archpsyc.65.6.634openalex-snapshot
Prevention of Negative Symptom Psychopathologies in First-Episode Schizophrenia
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2020.13233openalex-snapshot
Assessment of Anhedonia in Adults With and Without Mental Illness
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2026.35753openalex-snapshot
A Digital Therapeutic Intervention for Negative Symptoms of Schizophrenia
inferred← citeshttps://doi.org/10.1001/jamapsychiatry.2013.2159openalex-snapshot
Add-on Treatment of Benzoate for Schizophrenia
inferred← citeshttps://doi.org/10.1001/jamapsychiatry.2013.786openalex-snapshot
Neuroimaging Evidence for the Deficit Subtype of Schizophrenia
inferred← citeshttps://doi.org/10.1001/jamapsychiatry.2013.900openalex-snapshot
Randomized Multicenter Investigation of Folate Plus Vitamin B 12 Supplementation in Schizophrenia
inferred← citeshttps://doi.org/10.1001/jamapsychiatry.2014.163openalex-snapshot
Effect of Bitopertin, a Glycine Reuptake Inhibitor, on Negative Symptoms of Schizophrenia
inferred← citeshttps://doi.org/10.1001/jamapsychiatry.2018.2475openalex-snapshot
The Latent Structure of Negative Symptoms in Schizophrenia
inferred← citeshttps://doi.org/10.1001/jamapsychiatry.2023.0553openalex-snapshot
Effort-Cost Decision-making Among Individuals With Schizophrenia
inferred← citeshttps://doi.org/10.1002/14651858.cd008406openalex-snapshot
Antipsychotics for people with persistent negative symptoms of schizophrenia
inferred← citeshttps://doi.org/10.1002/14651858.cd008661.pub2openalex-snapshot
Modafinil for people with schizophrenia or related disorders
inferred← citeshttps://doi.org/10.1002/14651858.cd009005.pub2openalex-snapshot
Antipsychotic combinations for schizophrenia
inferred← citeshttps://doi.org/10.1002/14651858.cd011943openalex-snapshot
Mirtazapine (adjunct) versus placebo for schizophrenia
inferred← citeshttps://doi.org/10.1002/14651858.cd011943.pub2openalex-snapshot
Mirtazapine adjunct for people with schizophrenia
inferred← citeshttps://doi.org/10.1002/9781118753378.ch104openalex-snapshot
Antipsychotic Drugs
inferred← citeshttps://doi.org/10.1002/9781119057840.ch150openalex-snapshot
Schizophrenia
inferred← citeshttps://doi.org/10.1002/9781394258949.ch10openalex-snapshot
Schizophrenia and the Psychosis Spectrum
inferred← citeshttps://doi.org/10.1002/9781444327298.ch2openalex-snapshot
The Schizophrenia Construct: Symptomatic Presentation
inferred← citeshttps://doi.org/10.1002/9781444327298.ch24openalex-snapshot
Principles of Pharmacological Treatment in Schizophrenia
inferred← citeshttps://doi.org/10.1002/advs.202300455openalex-snapshot
YBX1‐Mediated DNA Methylation‐Dependent SHANK3 Expression in PBMCs and Developing Cortical Interneurons in Schizophrenia
inferred← citeshttps://doi.org/10.1002/ajmg.b.32394openalex-snapshot
Social cognition as an RDoC domain
inferred← citeshttps://doi.org/10.1002/cpp.1839openalex-snapshot
Awareness and Coping with Emotion in Schizophrenia: Acceptability, Feasibility and Case Illustrations
inferred← citeshttps://doi.org/10.1002/cpp.2731openalex-snapshot
The role of attachment and dissociation in the relationship between childhood interpersonal trauma and negative symptoms in psychosis
inferred← citeshttps://doi.org/10.1002/cpp.70090openalex-snapshot
Social Functioning Interventions in Psychosis: A Systematic Review
inferred← citeshttps://doi.org/10.1002/gps.2284openalex-snapshot
Prevalence and longitudinal stability of negative symptoms in healthy participants
inferred← citeshttps://doi.org/10.1002/hup.1101openalex-snapshot
Neurocognition and its influencing factors in the treatment of schizophrenia—effects of aripiprazole, olanzapine, quetiapine and risperidone
inferred← citeshttps://doi.org/10.1002/hup.2517openalex-snapshot
The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double‐blind and placebo‐controlled trial
inferred← citeshttps://doi.org/10.1002/hup.2583openalex-snapshot
Cilostazol adjunctive therapy in treatment of negative symptoms in chronic schizophrenia: Randomized, double-blind, placebo-controlled study
inferred← citeshttps://doi.org/10.1002/hup.807openalex-snapshot
Efficacy of amisulpride in treating primary negative symptoms in first-episode psychosis: a pilot study
inferred← citeshttps://doi.org/10.1002/hup.958openalex-snapshot
Effects of warm‐supplementing kidney yang (WSKY) capsule added on risperidone on cognition in chronic schizophrenic patients: a randomized, double‐blind, placebo‐controlled, multi‐center clinical trial
inferred← citeshttps://doi.org/10.1002/ijop.70045openalex-snapshot
Efficacy of Cognitive Behavioural Therapy in Controlling Negative Symptoms in Schizophrenic Patients: A Systematic Review and Meta‐Analysis
inferred← citeshttps://doi.org/10.1002/jclp.20591openalex-snapshot
Loving‐kindness meditation to enhance recovery from negative symptoms of schizophrenia
inferred← citeshttps://doi.org/10.1002/jclp.22727openalex-snapshot
Engaging with the affiliative system through mindfulness: The impact of the different types of positive affect in psychosis
inferred← citeshttps://doi.org/10.1002/jcp.27999openalex-snapshot
Pharmacoinformatics and molecular docking reveal potential drug candidates against Schizophrenia to target TAAR6
inferred← citeshttps://doi.org/10.1002/mpr.1856openalex-snapshot
Individuals with schizophrenia who act violently towards others profit unequally from inpatient treatment—Identifying subgroups by latent class analysis
inferred← citeshttps://doi.org/10.1002/npr2.12089openalex-snapshot
Blonanserin vs risperidone in Japanese patients with schizophrenia: A post hoc analysis of a phase 3, 8‐week, multicenter, double‐blind, randomized controlled study
inferred← citeshttps://doi.org/10.1002/pchj.70001openalex-snapshot
Motivation and Pleasure Domain Links to Social Function in College Students: A Network Analysis
inferred← citeshttps://doi.org/10.1002/pcn5.157openalex-snapshot
Emerging trends in antipsychotic and antidepressant drug development: Targeting nonmonoamine receptors and innovative mechanisms
inferred← citeshttps://doi.org/10.1002/wps.20385openalex-snapshot
The current conceptualization of negative symptoms in schizophrenia
inferred← citeshttps://doi.org/10.1002/wps.20809openalex-snapshot
The clinical characterization of the patient with primary psychosis aimed at personalization of management
inferred← citeshttps://doi.org/10.1007/7854_2010_47openalex-snapshot
Antipsychotic Drug Development
inferred← citeshttps://doi.org/10.1007/7854_2014_303openalex-snapshot
Electrophysiological Aberrations Associated with Negative Symptoms in Schizophrenia
inferred← citeshttps://doi.org/10.1007/7854_2015_379openalex-snapshot
Motivational Deficits and Negative Symptoms in Schizophrenia: Concepts and Assessments
inferred← citeshttps://doi.org/10.1007/7854_2022_382openalex-snapshot
An Update on Treatment of Cognitive Impairment Associated with Schizophrenia
inferred← citeshttps://doi.org/10.1007/978-1-4614-3846-5_5openalex-snapshot
The Strategy and Utility of the Endophenotype Approach to Neurobehavioral Function
inferred← citeshttps://doi.org/10.1007/978-1-4939-9127-3_11openalex-snapshot
Schizophrenia
inferred← citeshttps://doi.org/10.1007/978-1-908517-71-5_1openalex-snapshot
Symptom Rating Scales in Schizophrenia
inferred← citeshttps://doi.org/10.1007/978-3-030-29450-2_28openalex-snapshot
Negative Symptoms
inferred← citeshttps://doi.org/10.1007/978-3-030-32229-8_26openalex-snapshot
Cultural Considerations for Schizophrenia Spectrum Disorders Part I: Symptoms, Diagnosis, and Prevalence
inferred← citeshttps://doi.org/10.1007/978-3-030-32229-8_27openalex-snapshot
Cultural Considerations for Schizophrenia Spectrum Disorders II: Assessment and Treatment
inferred← citeshttps://doi.org/10.1007/978-3-030-42825-9_134-1openalex-snapshot
Medications for Psychosis: Dopamine Blockers and Dopamine Partial Agonists (Antipsychotics)
inferred← citeshttps://doi.org/10.1007/978-3-030-51366-5_134openalex-snapshot
Medications for Psychosis: Dopamine Blockers and Dopamine Partial Agonists (Antipsychotics)
inferred← citeshttps://doi.org/10.1007/978-3-030-76136-3_24openalex-snapshot
Schizophrenia: Negative Symptoms
inferred← citeshttps://doi.org/10.1007/978-3-031-32035-4_133-1openalex-snapshot
Schizoid Personality, Hikikomori, and Blood Biomarkers: A Focus on Lipidomics and Metabolomics
inferred← citeshttps://doi.org/10.1007/978-3-031-54896-3_10openalex-snapshot
Pupillometry in Schizophrenia: What We Know and Where We Could Go
inferred← citeshttps://doi.org/10.1007/978-3-031-69491-2_15openalex-snapshot
Mismatch Negativity (MMN) as a Pharmacodynamic/Response Biomarker for NMDA Receptor and Excitatory/Inhibitory Imbalance-Targeted Treatments in Schizophrenia
inferred← citeshttps://doi.org/10.1007/978-3-031-73368-0_133openalex-snapshot
Schizoid Personality, Hikikomori, and Blood Biomarkers: A Focus on Lipidomics and Metabolomics
inferred← citeshttps://doi.org/10.1007/978-3-032-06209-3_1openalex-snapshot
Negative Symptoms in Schizophrenia: Definition, Classification, and Course
inferred← citeshttps://doi.org/10.1007/978-3-032-06209-3_14openalex-snapshot
Relationship Between Cognitive Impairment and Negative Symptoms in Schizophrenia
inferred← citeshttps://doi.org/10.1007/978-3-032-06209-3_18openalex-snapshot
Cognitive Impairment and Negative Symptoms in Schizophrenia: A Summary and Future Research Perspectives
inferred← citeshttps://doi.org/10.1007/978-3-032-06209-3_2openalex-snapshot
The Assessment of Negative Symptoms in Schizophrenia
inferred← citeshttps://doi.org/10.1007/978-3-032-06209-3_4openalex-snapshot
Assessment of Negative Symptoms and of Real-Life Functioning: Critical Areas of Overlap
inferred← citeshttps://doi.org/10.1007/978-3-032-06209-3_5openalex-snapshot
Negative Symptoms in Schizophrenia: Neurobiological Bases
inferred← citeshttps://doi.org/10.1007/978-3-032-18372-9_1openalex-snapshot
What Is Serious Mental Illness?
inferred← citeshttps://doi.org/10.1007/978-3-319-13245-7_1openalex-snapshot
Theoretical Background
inferred← citeshttps://doi.org/10.1007/978-3-319-30521-9_5openalex-snapshot
Yoga and Mindfulness-Based Cognitive Therapy for Psychosis (Y-MBCT p ©): A Pilot Study on Its Efficacy as Brief Therapy
inferred← citeshttps://doi.org/10.1007/978-3-319-30596-7_5openalex-snapshot
Avolition, Negative Symptoms, and a Clinical Science Journey and Transition to the Future
inferred← citeshttps://doi.org/10.1007/978-3-319-56782-2_9258-1openalex-snapshot
Schizophrenia
inferred← citeshttps://doi.org/10.1007/978-3-319-57111-9_9258openalex-snapshot
Schizophrenia
inferred← citeshttps://doi.org/10.1007/978-3-319-58811-7_14openalex-snapshot
PDE Inhibitors for the Treatment of Schizophrenia
inferred← citeshttps://doi.org/10.1007/978-3-319-97307-4_2openalex-snapshot
Neuroimaging and Psychopathological Domains
inferred← citeshttps://doi.org/10.1007/978-3-642-25758-2_1openalex-snapshot
Clinical Instruments to Evaluate and Guide Treatment in Schizophrenia
inferred← citeshttps://doi.org/10.1007/978-94-007-0831-0_1openalex-snapshot
Negative Symptoms Across the Schizophrenia Spectrum: Phenomenological and Neurobiological Perspectives
inferred← citeshttps://doi.org/10.1007/978-94-007-5799-8openalex-snapshot
Polypharmacy in psychiatry practice
inferred← citeshttps://doi.org/10.1007/978-94-007-5805-6_9openalex-snapshot
Antidepressants in Schizophrenia: A Place for Them?
inferred← citeshttps://doi.org/10.1007/978-94-017-8610-2_1openalex-snapshot
Anhedonia in Schizophrenia: A Brief History and Overview of the Construct
inferred← citeshttps://doi.org/10.1007/978-94-017-8610-2_10openalex-snapshot
Anticipatory and Consummatory Anhedonia in Individuals with Schizotypal Traits
inferred← citeshttps://doi.org/10.1007/978-94-017-8610-2_2openalex-snapshot
Measuring Anhedonia in Schizophrenia-Spectrum Disorders: A Selective Update
inferred← citeshttps://doi.org/10.1007/978-94-017-8610-2_5openalex-snapshot
Anhedonia in Schizophrenia: A Deficit in Translating Reward Information into Motivated Behavior
inferred← citeshttps://doi.org/10.1007/978-981-16-4570-9_5openalex-snapshot
Mental Disorders, Violence, and Crime
inferred← citeshttps://doi.org/10.1007/978-981-99-4316-6_5openalex-snapshot
Psychische Störungen, Gewalt und Kriminalität
inferred← citeshttps://doi.org/10.1007/bf03379611openalex-snapshot
Deep Brain Stimulation in Schizophrenia
inferred← citeshttps://doi.org/10.1007/s00103-016-2311-1openalex-snapshot
Konzept und Ergebnisse des Kompetenznetzes Schizophrenie
inferred← citeshttps://doi.org/10.1007/s00115-008-2617-9openalex-snapshot
Neue Entwicklungen in der Psychotherapie schizophrener Psychosen
inferred← citeshttps://doi.org/10.1007/s00115-021-01065-5openalex-snapshot
Transkranielle elektrische Hirnstimulationsverfahren zur Behandlung der Negativsymptomatik bei Schizophrenie
inferred← citeshttps://doi.org/10.1007/s00127-023-02577-yopenalex-snapshot
Disability benefits protect against lost income for South Africans living with Schizophrenia
inferred← citeshttps://doi.org/10.1007/s00213-009-1530-7openalex-snapshot
Diverse and often opposite behavioural effects of NMDA receptor antagonists in rats: implications for “NMDA antagonist modelling” of schizophrenia
inferred← citeshttps://doi.org/10.1007/s00213-013-3064-2openalex-snapshot
A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia
inferred← citeshttps://doi.org/10.1007/s00213-016-4415-6openalex-snapshot
Lack of association between dopaminergic antagonism and negative symptoms in schizophrenia: a positron emission tomography dopamine D2/3 receptor occupancy study
inferred← citeshttps://doi.org/10.1007/s00213-018-5130-2openalex-snapshot
Selective adrenergic alpha2C receptor antagonist ameliorates acute phencyclidine-induced schizophrenia-like social interaction deficits in rats
inferred← citeshttps://doi.org/10.1007/s00406-007-0739-xopenalex-snapshot
Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms
inferred← citeshttps://doi.org/10.1007/s00406-007-0757-8openalex-snapshot
Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site
inferred← citeshttps://doi.org/10.1007/s00406-007-1003-0openalex-snapshot
Refinement of diagnosis and disease classification in psychiatry
inferred← citeshttps://doi.org/10.1007/s00406-008-2004-3openalex-snapshot
Systematic of psychiatric disorders between categorical and dimensional approaches
inferred← citeshttps://doi.org/10.1007/s00406-015-0590-4openalex-snapshot
Neurobiological background of negative symptoms
inferred← citeshttps://doi.org/10.1007/s00406-015-0595-zopenalex-snapshot
Psychometric evaluation of the negative syndrome of schizophrenia
inferred← citeshttps://doi.org/10.1007/s00406-015-0596-yopenalex-snapshot
Pharmacological treatment of negative symptoms in schizophrenia
inferred← citeshttps://doi.org/10.1007/s00406-015-0618-9openalex-snapshot
Transcutaneous noninvasive vagus nerve stimulation (tVNS) in the treatment of schizophrenia: a bicentric randomized controlled pilot study
inferred← citeshttps://doi.org/10.1007/s00406-017-0813-yopenalex-snapshot
Correspondence between negative symptoms and potential sources of secondary negative symptoms over time
inferred← citeshttps://doi.org/10.1007/s00406-018-0869-3openalex-snapshot
Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1007/s00406-018-0907-1openalex-snapshot
The cognitive, affective motivational and clinical longitudinal determinants of apathy in schizophrenia
inferred← citeshttps://doi.org/10.1007/s00406-018-0918-yopenalex-snapshot
Executive dysfunctions differentially predict amotivation in first-episode schizophrenia-spectrum disorder: a prospective 1-year follow-up study
inferred← citeshttps://doi.org/10.1007/s00406-020-01145-8openalex-snapshot
Brain activity and connectivity differences in reward value discrimination during effort computation in schizophrenia
inferred← citeshttps://doi.org/10.1007/s00406-020-01188-xopenalex-snapshot
Cognitive, community functioning and clinical correlates of the Clinical Assessment Interview for Negative Symptoms (CAINS) in psychotic disorders
inferred← citeshttps://doi.org/10.1007/s00406-021-01260-0openalex-snapshot
The impact of the COVID-19 pandemic on negative symptoms in individuals at clinical high-risk for psychosis and outpatients with chronic schizophrenia
inferred← citeshttps://doi.org/10.1007/s00406-021-01309-0openalex-snapshot
Relationship of subjective quality of life with symptomatology, neurocognition and psychosocial functioning in first-episode psychosis: a structural equation modelling approach
inferred← citeshttps://doi.org/10.1007/s00406-022-01474-wopenalex-snapshot
Bridge centrality network structure of negative symptoms in people with schizophrenia
inferred← citeshttps://doi.org/10.1007/s00406-022-01507-4openalex-snapshot
Two and five-factor models of negative symptoms in schizophrenia are differentially associated with trait affect, defeatist performance beliefs, and psychosocial functioning
inferred← citeshttps://doi.org/10.1007/s00406-023-01733-4openalex-snapshot
Linking social motivation, general motivation, and social cognition to interpersonal functioning in schizophrenia: insights from exploratory graph analysis
inferred← citeshttps://doi.org/10.1007/s00406-024-01934-5openalex-snapshot
A transdiagnostic approach of negative symptoms in psychiatric disorders: replication of a two-factor structure in major depressive disorder and bipolar disorder
inferred← citeshttps://doi.org/10.1007/s00406-026-02328-5openalex-snapshot
Efficacy and EEG-ECG mechanisms of taVNS combined with TEAS for negative symptoms of schizophrenia: a protocol for a 2 × 2 factorial randomized controlled trial
inferred← citeshttps://doi.org/10.1007/s00426-008-0195-xopenalex-snapshot
Distinct conflict resolution deficits related to different facets of Schizophrenia
inferred← citeshttps://doi.org/10.1007/s00702-021-02435-8openalex-snapshot
Factor structure and internal consistency of the Clinical Assessment Interview for Negative Symptoms (CAINS) on a sample of persons with psychotic disorders in Bosnia and Herzegovina
inferred← citeshttps://doi.org/10.1007/s00787-023-02196-7openalex-snapshot
Prodromal symptoms and the duration of untreated psychosis in first episode of psychosis patients: what differences are there between early vs. adult onset and between schizophrenia vs. bipolar disorder?
inferred← citeshttps://doi.org/10.1007/s10072-021-05787-xopenalex-snapshot
Negative symptoms in Huntington’s disease
inferred← citeshttps://doi.org/10.1007/s10548-023-00984-7openalex-snapshot
Electrophysiological Correlates of Reward Anticipation in Subjects with Schizophrenia: An ERP Microstate Study
inferred← citeshttps://doi.org/10.1007/s10597-025-01483-8openalex-snapshot
A Systematic Review of Tai Chi-based Interventions for Positive and Negative Symptoms, Cognitive Functioning, and Quality of Life in Psychosis
inferred← citeshttps://doi.org/10.1007/s10608-018-9940-7openalex-snapshot
Development of the Demotivating Beliefs Inventory and Test of the Cognitive Triad of Amotivation
inferred← citeshttps://doi.org/10.1007/s10608-020-10098-0openalex-snapshot
The Theory of Modes: Applications to Schizophrenia and Other Psychological Conditions
inferred← citeshttps://doi.org/10.1007/s11055-025-01817-9openalex-snapshot
The Role of Immunoinflammatory Factors in the Development of Negative Symptoms in Schizophrenia
inferred← citeshttps://doi.org/10.1007/s11064-022-03538-8openalex-snapshot
In Vivo 13C Magnetic Resonance Spectroscopy for Assessing Brain Biochemistry in Health and Disease
inferred← citeshttps://doi.org/10.1007/s11481-025-10231-4openalex-snapshot
Sigma-1 Receptor Activation by Fluvoxamine Ameliorates ER Stress, Synaptic Dysfunction and Behavioral Deficits in a Ketamine Model of Schizophrenia
inferred← citeshttps://doi.org/10.1007/s11920-006-0069-0openalex-snapshot
Anhedonia in schizophrenia
inferred← citeshttps://doi.org/10.1007/s11920-008-0056-8openalex-snapshot
Better pharmacotherapy for schizophrenia: What does the future hold?
inferred← citeshttps://doi.org/10.1007/s12144-021-01989-wopenalex-snapshot
Electroconvulsive therapy for negative symptoms in schizophrenia: a literature review from 2000 to 2021
inferred← citeshttps://doi.org/10.1007/s13670-012-0006-5openalex-snapshot
Cognitive Deficits in Schizophrenia
inferred← citeshttps://doi.org/10.1007/s40261-025-01465-4openalex-snapshot
Memantine for the Treatment of Primary Negative Symptoms in Schizophrenia: A Meta-analysis of Randomized Controlled Trials
inferred← citeshttps://doi.org/10.1007/s40263-016-0315-xopenalex-snapshot
Potential of Oxytocin in the Treatment of Schizophrenia
inferred← citeshttps://doi.org/10.1007/s40263-017-0428-xopenalex-snapshot
Managing Negative Symptoms of Schizophrenia: How Far Have We Come?
inferred← citeshttps://doi.org/10.1007/s40473-014-0012-3openalex-snapshot
Early Detection of Psychosis: Challenges and Opportunities
inferred← citeshttps://doi.org/10.1007/s40473-016-0080-7openalex-snapshot
Can Oxytocin Enhance Social Affiliation in Schizophrenia?
inferred← citeshttps://doi.org/10.1007/s40473-023-00262-7openalex-snapshot
Transcranial Magnetic Stimulation in the Treatment of Positive, Negative, and Cognitive Symptoms of Psychosis
inferred← citeshttps://doi.org/10.1007/s40501-016-0075-8openalex-snapshot
Treating Negative Symptoms in Schizophrenia: an Update
inferred← citeshttps://doi.org/10.1007/s40501-019-0164-6openalex-snapshot
Multidisciplinary Treatment for Individuals at Clinical High Risk of Developing Psychosis
inferred← citeshttps://doi.org/10.1007/s40737-017-0088-7openalex-snapshot
The Relationship between Social Competence, Symptom Severity and Employment in Schizophrenia
inferred← citeshttps://doi.org/10.1007/s40737-018-0116-2openalex-snapshot
Activity Based Group Intervention in Improving Negative Symptoms and Functional Outcome in Patients with Chronic Schizophrenia in Welfare Homes
inferred← citeshttps://doi.org/10.1007/s41480-020-0116-1openalex-snapshot
Is de Korte Schaal voor Negatieve Symptomen een bruikbaar instrument?
inferred← citeshttps://doi.org/10.1007/s43440-020-00177-0openalex-snapshot
Magnetic resonance diffusion tensor imaging in psychiatry: a narrative review of its potential role in diagnosis
inferred← citeshttps://doi.org/10.1007/s44192-026-00420-9openalex-snapshot
The influence of group physical activity on oxytocin, empathy, affect, and stress in individuals with schizophrenia spectrum disorders in a single-arm, pilot and exploratory study
inferred← citeshttps://doi.org/10.1016/b978-0-12-405172-0.00007-7openalex-snapshot
The Impact of Metacognition on the Development and Maintenance of Negative Symptoms
inferred← citeshttps://doi.org/10.1016/b978-0-12-802203-0.00012-2openalex-snapshot
Diagnostic and symptom interviews for adults
inferred← citeshttps://doi.org/10.1016/b978-0-12-815012-2.00007-9openalex-snapshot
Negative Symptoms and Their Assessment in Schizophrenia and Related Disorders
inferred← citeshttps://doi.org/10.1016/b978-0-12-815012-2.00009-2openalex-snapshot
Assessing Social Functioning Across the Life Course of Psychosis
inferred← citeshttps://doi.org/10.1016/b978-0-12-815315-4.00005-7openalex-snapshot
Shared neural substrates of deficits in social cognition and negative symptoms in schizophrenia
inferred← citeshttps://doi.org/10.1016/b978-0-12-818697-8.00089-3openalex-snapshot
Psychotic Disorders and Risk-States in Adolescence: Etiology, Developmental Considerations, and Treatment
inferred← citeshttps://doi.org/10.1016/b978-0-323-04743-2.50030-5openalex-snapshot
Psychosis and Schizophrenia
inferred← citeshttps://doi.org/10.1016/b978-0-323-89832-4.00006-8openalex-snapshot
Introduction to psychotic disorders in adolescence
inferred← citeshttps://doi.org/10.1016/b978-0-7020-3137-3.00011-5openalex-snapshot
Clinical psychopharmacology
inferred← citeshttps://doi.org/10.1016/b978-2-294-75915-4.00070-0openalex-snapshot
Améliorer le plaisir et la motivation dans la schizophrénie
inferred← citeshttps://doi.org/10.1016/b978-343723730-0.50023-9openalex-snapshot
Psychotherapie der Schizophrenie
inferred← citeshttps://doi.org/10.1016/j.ajp.2014.08.005openalex-snapshot
Role of ranitidine in negative symptoms of schizophrenia – An open label study
inferred← citeshttps://doi.org/10.1016/j.ajp.2020.102423openalex-snapshot
Gamma transcranial alternating current stimulation for treatment of negative symptoms in schizophrenia: Report of two cases
inferred← citeshttps://doi.org/10.1016/j.ajp.2020.102522openalex-snapshot
Validation of the traditional script Chinese version of the brief negative symptom scale
inferred← citeshttps://doi.org/10.1016/j.ajp.2021.102680openalex-snapshot
Latent structure of self-report negative symptoms in patients with schizophrenia: A preliminary study
inferred← citeshttps://doi.org/10.1016/j.ajp.2021.102732openalex-snapshot
Large-scale evaluation of the Positive and Negative Syndrome Scale (PANSS) symptom architecture in schizophrenia
inferred← citeshttps://doi.org/10.1016/j.ajp.2021.102996openalex-snapshot
Social skills, negative symptoms and real-world functioning in individuals at ultra-high risk of psychosis
inferred← citeshttps://doi.org/10.1016/j.ajp.2023.103448openalex-snapshot
Negative symptoms in drug-naive patients with a first-episode psychosis (FEP)
inferred← citeshttps://doi.org/10.1016/j.ajp.2023.103467openalex-snapshot
Emotion-behaviour decoupling and experiential pleasure deficits predict negative symptoms and functional outcome in first-episode schizophrenia patients
inferred← citeshttps://doi.org/10.1016/j.ajp.2023.103616openalex-snapshot
The motivation and pleasure deficits but not expressivity affects social functioning through cognitive function in male patients with schizophrenia: A structural equation model
inferred← citeshttps://doi.org/10.1016/j.ajp.2026.104979openalex-snapshot
Adjunctive pimavanserin in schizophrenia: A systematic review and meta-analysis with a focus on negative-symptom programmes
inferred← citeshttps://doi.org/10.1016/j.amp.2019.01.010openalex-snapshot
Thérapie comportementale et cognitive des symptômes négatifs de la schizophrénie. Revue de la question : pratiques actuelles et directions futures
inferred← citeshttps://doi.org/10.1016/j.bbi.2016.08.020openalex-snapshot
Maternal immune activation alters sensitivity to action-outcome contingency in adult rat offspring
inferred← citeshttps://doi.org/10.1016/j.bbi.2018.11.315openalex-snapshot
Association of baseline inflammatory markers and the development of negative symptoms in individuals at clinical high risk for psychosis
inferred← citeshttps://doi.org/10.1016/j.bbi.2025.07.023openalex-snapshot
The moderating role of lifetime social engagement on the relationship between C-reactive protein and negative symptoms among young adults at clinical high risk for psychosis
inferred← citeshttps://doi.org/10.1016/j.bbr.2014.08.064openalex-snapshot
Peripheral DISC1 protein levels as a trait marker for schizophrenia and modulating effects of nicotine
inferred← citeshttps://doi.org/10.1016/j.bbr.2016.06.021openalex-snapshot
Towards the development of improved tests for negative symptoms of schizophrenia in a validated animal model
inferred← citeshttps://doi.org/10.1016/j.bbr.2021.113710openalex-snapshot
Pimavanserin augments the efficacy of atypical antipsychotic drugs in a mouse model of treatment-refractory negative symptoms of schizophrenia
inferred← citeshttps://doi.org/10.1016/j.bcp.2013.06.016openalex-snapshot
Animal models of CNS disorders
inferred← citeshttps://doi.org/10.1016/j.bcp.2017.05.009openalex-snapshot
Challenges and opportunities for the development of new antipsychotic drugs
inferred← citeshttps://doi.org/10.1016/j.beproc.2011.02.004openalex-snapshot
Modeling motivational deficits in mouse models of schizophrenia: Behavior analysis as a guide for neuroscience
inferred← citeshttps://doi.org/10.1016/j.biopsych.2014.10.009openalex-snapshot
Left Prefrontal High-Frequency Repetitive Transcranial Magnetic Stimulation for the Treatment of Schizophrenia with Predominant Negative Symptoms: A Sham-Controlled, Randomized Multicenter Trial
inferred← citeshttps://doi.org/10.1016/j.biopsych.2015.02.017openalex-snapshot
In Search of Multimodal Neuroimaging Biomarkers of Cognitive Deficits in Schizophrenia
inferred← citeshttps://doi.org/10.1016/j.biopsych.2015.07.025openalex-snapshot
A Review of Oxytocin’s Effects on the Positive, Negative, and Cognitive Domains of Schizophrenia
inferred← citeshttps://doi.org/10.1016/j.biopsych.2015.08.037openalex-snapshot
Pupillary Responses as a Biomarker of Diminished Effort Associated With Defeatist Attitudes and Negative Symptoms in Schizophrenia
inferred← citeshttps://doi.org/10.1016/j.biopsych.2016.02.016openalex-snapshot
Evaluating New Pharmacotherapies for Schizophrenia
inferred← citeshttps://doi.org/10.1016/j.biopsych.2016.11.014openalex-snapshot
Bitopertin in Negative Symptoms of Schizophrenia—Results From the Phase III FlashLyte and DayLyte Studies
inferred← citeshttps://doi.org/10.1016/j.biopsych.2024.03.014openalex-snapshot
Muscarinic Receptor Activators as Novel Treatments for Schizophrenia
inferred← citeshttps://doi.org/10.1016/j.biopsych.2025.06.009openalex-snapshot
A Longitudinal and Reproducible Anti-Coactivation Pattern Between the Cerebellum and the Ventral Tegmental Area Is Related to Apathy in Schizophrenia
inferred← citeshttps://doi.org/10.1016/j.biopsych.2026.08.019openalex-snapshot
Dexamphetamine-induced striatal hyperdopaminergia attenuates reward-related neural activation: A11C-PHNO PET-fMRI study
inferred← citeshttps://doi.org/10.1016/j.bpsc.2016.05.005openalex-snapshot
Probabilistic Reinforcement Learning in Patients With Schizophrenia: Relationships to Anhedonia and Avolition
inferred← citeshttps://doi.org/10.1016/j.bpsc.2025.07.013openalex-snapshot
Cerebellar-Prefrontal Connectivity Predicts Negative Symptom Severity Across the Psychosis Spectrum
inferred← citeshttps://doi.org/10.1016/j.bpsgos.2021.05.008openalex-snapshot
Secondary Sources of Negative Symptoms in Those Meeting Criteria for a Clinical High-Risk Syndrome
inferred← citeshttps://doi.org/10.1016/j.brainres.2007.04.042openalex-snapshot
Prenatal stress generates deficits in rat social behavior: Reversal by oxytocin
inferred← citeshttps://doi.org/10.1016/j.brainresbull.2010.04.006openalex-snapshot
N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: The final common pathway on the road to schizophrenia?
inferred← citeshttps://doi.org/10.1016/j.brs.2025.09.011openalex-snapshot
Assessing tDCS efficacy in reducing negative symptoms in schizophrenia spectrum disorders: A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.ceb.2013.11.002openalex-snapshot
Integrated approaches to understanding antipsychotic drug action at GPCRs
inferred← citeshttps://doi.org/10.1016/j.celrep.2021.109950openalex-snapshot
mGlu1 potentiation enhances prelimbic somatostatin interneuron activity to rescue schizophrenia-like physiological and cognitive deficits
inferred← citeshttps://doi.org/10.1016/j.chiabu.2023.106470openalex-snapshot
Prevalence of co-occurring severe depression and psychotic symptoms in college students and its relationship with childhood maltreatment
inferred← citeshttps://doi.org/10.1016/j.clinph.2016.01.006openalex-snapshot
Reward anticipation and trait anhedonia: An electrophysiological investigation in subjects with schizophrenia
inferred← citeshttps://doi.org/10.1016/j.comppsych.2012.12.001openalex-snapshot
The Motivation and Pleasure Scale–Self-Report (MAP-SR): Reliability and validity of a self-report measure of negative symptoms
inferred← citeshttps://doi.org/10.1016/j.comppsych.2014.04.001openalex-snapshot
Daily activity patterns in remitted first-episode schizophrenia
inferred← citeshttps://doi.org/10.1016/j.comppsych.2014.05.024openalex-snapshot
Spanish adaptation and validation of the Brief Negative Symptoms Scale
inferred← citeshttps://doi.org/10.1016/j.comppsych.2015.11.001openalex-snapshot
Motivation and Pleasure Scale-Self-Report (MAP-SR): Validation of the German version of a self-report measure for screening negative symptoms in schizophrenia
inferred← citeshttps://doi.org/10.1016/j.comppsych.2018.06.007openalex-snapshot
The Brief Negative Symptom Scale: Validation in a multicenter Brazilian study
inferred← citeshttps://doi.org/10.1016/j.comppsych.2018.10.007openalex-snapshot
Self-assessment of negative symptoms – Critical appraisal of the motivation and pleasure – Self-report's (MAP-SR) validity and reliability
inferred← citeshttps://doi.org/10.1016/j.comppsych.2018.10.010openalex-snapshot
Reduced willingness to invest effort in schizophrenia with high negative symptoms regardless of reward stimulus presentation and reward value
inferred← citeshttps://doi.org/10.1016/j.comppsych.2021.152289openalex-snapshot
Does social defeat cause negative symptoms? A prospective study in a multi-national community sample
showing the first 200 of 1272
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.